Assertio Holdings (ASRT) Change in Accured Expenses (2019 - 2026)

Assertio Holdings' (ASRT) quarterly Change in Accured Expenses came in at -$650000.0 in Q1 2026, down 107.26% year-on-year from $9.0 million in Q1 2025, and up 93.47% quarter-over-quarter from -$10.0 million in Q4 2025.

Assertio Holdings (ASRT) Change in Accured Expenses (2019 - 2026) Analysis & Trends

Assertio Holdings has disclosed Change in Accured Expenses across 8 years of filings, most recently posting -$650000.0 for Q1 2026.

  • Change in Accured Expenses for Q1 2026 came in at -$650000.0, down 107.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.9 million (down 392.34% YoY), and the FY2025 annual result was -$13.3 million, down 958.28% from the prior year.
  • Change in Accured Expenses came in at -$650000.0 for Q1 2026 at Assertio Holdings, up from -$10.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.0 million in Q1 2025 to a low of -$26.4 million in Q3 2023.
  • The 5-year median for Change in Accured Expenses is -$650000.0 (2026), against an average of -$2.6 million.
  • Peak annual rise in Change in Accured Expenses reached 6782.09% in 2025, while the deepest fall reached 1542.74% in 2025.
  • Assertio Holdings' Change in Accured Expenses stood at $7.1 million in 2022, then tumbled by 210.24% to -$7.8 million in 2023, then soared by 92.26% to -$606000.0 in 2024, then slumped by 1542.74% to -$10.0 million in 2025, then soared by 93.47% to -$650000.0 in 2026.
  • The last three Change in Accured Expenses figures came in at -$650000.0 (Q1 2026), -$10.0 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn -144.00 Mn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn -234.00 Mn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -12.70 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn -14.30 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn -
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 4.89 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 23.00 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn 10.02 Mn
10 Assertio Holdings 150.78 Mn 79.21 Mn 7.22 Mn -650,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -650,000.00
Mar 31, 2026 -650,000.00
Dec 31, 2025 -9.96 Mn
Dec 31, 2025 -9.96 Mn
Sep 30, 2025 -10.35 Mn
Sep 30, 2025 -10.35 Mn
Jun 30, 2025 -1.94 Mn
Jun 30, 2025 -1.94 Mn
Mar 31, 2025 8.95 Mn
Mar 31, 2025 8.95 Mn
Dec 31, 2024 -606,000.00
Dec 31, 2024 -606,000.00
Sep 30, 2024 977,000.00
Sep 30, 2024 977,000.00
Jun 30, 2024 -1.49 Mn
Jun 30, 2024 -1.49 Mn
Mar 31, 2024 -134,000.00
Mar 31, 2024 -134,000.00
Dec 31, 2023 -7.83 Mn
Dec 31, 2023 -7.83 Mn